Brian M. Slomovitz
Experienced in Cervical Polyps

Dr. Brian M. Slomovitz

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Physician Practices Of Msmc LLC
4306 Alton Rd, Fl 3, 
Miami Beach, FL 
 (1392.2 mi)
Clinical Trials:Currently Recruiting for 4 Trials
Accepting New Patients
Offers Telehealth
Experienced in Cervical Polyps
Physician Practices Of Msmc LLC
4306 Alton Rd, Fl 3, 
Miami Beach, FL 
 (1392.2 mi)
OverviewInsuranceLocationsClinical Research

Overview

Brian Slomovitz is a Gynecologic Oncologist and an Oncologist in Miami Beach, Florida. Dr. Slomovitz and is rated as an Experienced provider by MediFind in the treatment of Cervical Polyps. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Hysterectomy, and Lymphadenectomy. Dr. Slomovitz is currently accepting new patients.

His clinical research consists of co-authoring 94 peer reviewed articles and participating in 21 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in NY
Hospital Affiliations
Mount Sinai Medical Center Of Florida, Inc
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Health Options
  •  UnitedHealthcare
  •  Florida Blue

Locations

PHYSICIAN PRACTICES OF MSMC LLC
4306 Alton Rd, Fl 3, Miami Beach, FL 33140

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

A Randomized Controlled Trial of Robotic Versus Open Surgery for Early Stage Cervical Cancer (ROCC)
A Randomized Controlled Trial of Robotic Versus Open Surgery for Early Stage Cervical Cancer (ROCC)
Enrollment Status: Recruiting
Publish Date: December 19, 2024
Intervention Type: Other, Device
Study Phase: Not Applicable
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
Enrollment Status: Recruiting
Publish Date: October 02, 2024
Intervention Type: Behavioral
Study Phase: Not Applicable
A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer
A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drugs: Atezolizumab, Bevacizumab, Ipatasertib, Talazoparib, Trastuzumab Emtansine, Tiragolumab
Study Phase: Phase 1/Phase 2
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: August 22, 2023
Intervention Type: Biological
Study Drug: Dostarlimab
Study Phase: Phase 1
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Other, Drug
Study Drugs: Letrozole, Paclitaxel, Pegylated liposomal doxorubicin hydrochloride, Tamoxifen citrate, Topotecan, Trametinib dimethyl sulfoxide
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 09, 2025
Intervention Type: Other, Biological
Study Drug: Vigil
Study Phase: Phase 2
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drugs: Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan, Pemetrexed
Study Phase: Phase 3
A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary
A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 2
Phase II Single Arm Study of Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
Phase II Single Arm Study of Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
Enrollment Status: Terminated
Publish Date: June 18, 2024
Intervention Type: Drug
Study Drugs: Pembrolizumab, Paclitaxel, Cisplatin, Carboplatin, Bevacizumab
Study Phase: Phase 2
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: March 29, 2024
Intervention Type: Device, Drug
Study Drug: Paclitaxel
Study Phase: Phase 3
Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors
Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2024
Intervention Type: Genetic, Radiation
Study Drug: Autologous Genetically Modified MAGE-A4c1032 T-Cells
Study Phase: Phase 1
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: July 25, 2023
Intervention Type: Drug
Study Drug: Tisotumab Vedotin
Study Phase: Phase 2
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Enrollment Status: Terminated
Publish Date: March 14, 2023
Intervention Type: Drug
Study Drug: ADXS11-001 L. monocytogenes Vaccine
Study Phase: Phase 3
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
Enrollment Status: Completed
Publish Date: February 15, 2022
Intervention Type: Drug, Other
Study Drug: Copanlisib
Study Phase: Phase 2
First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax® TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor
First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax® TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor
Enrollment Status: Completed
Publish Date: December 29, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I/II Study of Gleevec/Taxol in Patients With Newly Diagnosed Stage IIIC or IV or Recurrent (Any Stage) Uterine Papillary Serous Carcinoma (UPSC)
A Phase I/II Study of Gleevec/Taxol in Patients With Newly Diagnosed Stage IIIC or IV or Recurrent (Any Stage) Uterine Papillary Serous Carcinoma (UPSC)
Enrollment Status: Terminated
Publish Date: November 18, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 3
The Validity of Sentinel Lymph Node Dissection (SLND) in Patients With Apparent Early Stage Endometrial Cancer (EC)
The Validity of Sentinel Lymph Node Dissection (SLND) in Patients With Apparent Early Stage Endometrial Cancer (EC)
Enrollment Status: Completed
Publish Date: March 12, 2020
A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.
A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.
Enrollment Status: Completed
Publish Date: June 27, 2019
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Enrollment Status: Terminated
Publish Date: March 22, 2018
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 17 Less Clinical Trials

94 Total Publications

State of the art endocrine treatments for patients diagnosed with endometrial cancer in 2025.
State of the art endocrine treatments for patients diagnosed with endometrial cancer in 2025.
Journal: Current opinion in obstetrics & gynecology
Published: January 08, 2025
Similar Doctors
Distinguished in Cervical Polyps
Dr. Jose A. Carugno
Obstetrics and Gynecology
Distinguished in Cervical Polyps
Dr. Jose A. Carugno
Obstetrics and Gynecology

University Of Miami

1400 Nw 12th Ave, 
Miami, FL 
 (5.2 mi)
Languages Spoken:
English, Italian, Spanish
See accepted insurances
Accepting New Patients

Jose Carugno is an Obstetrics and Gynecologist in Miami, Florida. Dr. Carugno and is rated as an Advanced provider by MediFind in the treatment of Cervical Polyps. His top areas of expertise are Cervical Polyps, Endometrial Polyps, Ectopic Pregnancy, Endoscopy, and Tubal Ligation. Dr. Carugno is currently accepting new patients.

Advanced in Cervical Polyps
Dr. Geoffrey J. Zann
Obstetrics and Gynecology
Advanced in Cervical Polyps
Dr. Geoffrey J. Zann
Obstetrics and Gynecology

Integrated Womens Health LLC

211 E Boynton Beach Blvd, 
Boynton Beach, FL 
 (49.5 mi)
561-732-3200
Experience:
43+ years
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Geoffrey Zann is an Obstetrics and Gynecologist in Boynton Beach, Florida. Dr. Zann has been practicing medicine for over 43 years and is rated as a Distinguished provider by MediFind in the treatment of Cervical Polyps. His top areas of expertise are Endometritis, Human Papillomavirus Infection, Angiomyoma, Uterine Fibroids, and Osteotomy. Dr. Zann is currently accepting new patients.

Advanced in Cervical Polyps
Dr. Patricia P. Jeudin
Obstetrics and Gynecology
Advanced in Cervical Polyps
Dr. Patricia P. Jeudin
Obstetrics and Gynecology

University Of Miami

1400 Nw 12th Ave Ent-7, University Of Miami Hospital, 
Miami, FL 
 (5.3 mi)
305-355-1684
Languages Spoken:
English, French, Haitian
See accepted insurances
Accepting New Patients
Offers Telehealth

Patricia Jeudin is an Obstetrics and Gynecologist in Miami, Florida. Dr. Jeudin and is rated as an Advanced provider by MediFind in the treatment of Cervical Polyps. Her top areas of expertise are Endometrial Polyps, Cervical Dysplasia, Neonatal Ovarian Cyst, and Angiomyoma. Dr. Jeudin is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile